NLRP3 and colitis: Administration of the NLRP3 inhibitor MCC95039 attenuated the clinical and histological signs of colitis in Dox-treated iUVRAGFS mice, including weight loss, colon length reduction, histological indices, tissue injury, and inflammatory infiltrates (Supplementary Fig. 4j–n; Fig. 4j–l).